Log in to save to my catalogue

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10054357

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

About this item

Full title

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

Publisher

Switzerland: MDPI AG

Journal title

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5518

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

A combination of tyrosine kinase inhibitors (TKIs) is likely to be a therapeutic option for numerous oncological situations due to high frequency of oncogenic addiction and progress in precision oncology. Non-small cell lung cancer (NSCLC) represents a subtype of tumors for which oncogenic drivers are frequently involved. To the best of our knowled...

Alternative Titles

Full title

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10054357

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10054357

Other Identifiers

ISSN

1422-0067,1661-6596

E-ISSN

1422-0067

DOI

10.3390/ijms24065518

How to access this item